Reaction
Immune-Mediated Neuropathy reporting signals
As of the last recalculation, Immune-Mediated Neuropathy appears in 144 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 191.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 71 | 191.4 | 191.6 |
| Pemetrexed | 10 | 72.4 | 72.4 |
| Ipilimumab | 16 | 60.2 | 60.2 |
| Nivolumab | 29 | 54.0 | 54.1 |
| Atezolizumab | 11 | 44.2 | 44.3 |